Clinical Trials Browser

Salivary Gland Neoplasms × pembrolizumab × 90 days × Clear all

NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Phase 2 Active not recruiting

45 enrolled 12 charts

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT03360890 2026-03-13

iPRIME

Phase 2 Active not recruiting

Salivary Gland Neoplasms, Thyroid Neoplasms